Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-methyl-n-(endo-9-methyl-9-azabicyclo(3.3.1)non-3-yl)-1h-indazole-3-carboxamide
2. 1h-indazole-3-carboxamide, 1-methyl-n-(9-methyl-9-azabicyclo(3.3.1)non-3-yl
3. 1h-indazole-3-carboxamide, 1-methyl-n-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, Endo-
4. Brl 43694
5. Brl 43694a
6. Brl-43694
7. Brl-43694a
8. Brl43694
9. Brl43694a
10. Granisetron
11. Granisetron Hydrochloride
12. Granisetron Monohydrochloride
13. Hydrochloride, Granisetron
14. Kytril
15. Monohydrochloride, Granisetron
1. Granisetron
2. 109889-09-0
3. Exo-granisetron (granisetron Impurity F)
4. 1364914-39-5
5. 1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide
6. Granisetronum [inn-latin]
7. 1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1h-indazole-3-carboxamide
8. Brl 43694
9. Granisetron-d3
10. Granisetron Base
11. [3h]-granisetron
12. Ly-278584
13. [3h]granisetron
14. Apf-530
15. 1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1h-indazole-3-carboxamide
16. 1-methyl-n-{9-methyl-9-azabicyclo[3.3.1]nonan-3-yl}-1h-indazole-3-carboxamide
17. [3h]-brl-43694
18. Schembl445223
19. Chembl289469
20. Chembl519643
21. Gtpl2292
22. 1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3-carboxamide
23. Dtxsid50861188
24. Chebi:184693
25. Bcp10022
26. Ex-a1291
27. Hy-b0071
28. Bbl036319
29. Bdbm50000483
30. Pdsp1_001266
31. Pdsp2_001250
32. Stl483411
33. Akos015895362
34. Ab07494
35. Cs-1509
36. Sdccgsbi-0633801.p001
37. Ncgc00186041-01
38. Ncgc00186041-09
39. Ls-14665
40. Ft-0626805
41. Ab01274752-01
42. Ab01274752_02
43. Ab01274752_03
44. Aa-504/10505045
45. L000281
46. 1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-7-yl)indazole-3-carboxamide
47. 1-methyl-1h-indazole-3-carboxylic Acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide
48. 1-methyl-1h-indazole-3-carboxylic Acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide
49. 1-methyl-n-((1s,5r)-9-methyl-9-aza-bicyclo[3.3.1]nonan-3-yl)-1h-indazole-3-carboxamide
50. N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1-methyl-1h-indazole-3-carboxamide
51. (brl 43694)1-methyl-1h-indazole-3-carboxylic Acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide
52. (granisetron)1-methyl-1h-indazole-3-carboxylic Acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide
53. 1-methyl-1h-indazole-3-carboxylic Acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide(brl 43694)
54. 1-methyl-1h-indazole-3-carboxylic Acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide(granisetron)
55. 2-(9-methyl-3,9-diaza-bicyclo[3.3.1]non-3-yl)-1-(1-methyl-1h-indol-3-yl)-ethanone(granisetron)
Molecular Weight | 312.4 g/mol |
---|---|
Molecular Formula | C18H24N4O |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 2 |
Exact Mass | 312.19501140 g/mol |
Monoisotopic Mass | 312.19501140 g/mol |
Topological Polar Surface Area | 50.2 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 442 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days.
Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.
Serotonin 5-HT3 Receptor Antagonists
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS. (See all compounds classified as Serotonin 5-HT3 Receptor Antagonists.)
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
A04AA02
A - Alimentary tract and metabolism
A04 - Antiemetics and antinauseants
A04A - Antiemetics and antinauseants
A04AA - Serotonin (5ht3) antagonists
A04AA02 - Granisetron
About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
About the Company : Since its inception in 2003, Seqens has evolved into a global leader in pharmaceutical solutions and specialty ingredients. With a strong focus on customer support, Seqens assists ...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...
About the Company : Fujian South Pharmaceutical Co., Ltd. (Southern Pharmaceutical) was established in September 2001 and is located in Mingxi County, Fujian Province. After 16 years of development, ...
About the Company : Mehta Pharmaceutical Industries engaged in Manufacturing and marketing of APls & Advance Drug Intermediates... Locally since 1970 and Globally since 1982. Primary Vendor to top Ind...
About the Company : Established in the year 2004, Sakar is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injec...
About the Company : SWATI SPENTOSE PVT. LTD.(SSPL), a pharmaceutical company based in Mumbai, India having 2 manufacturing sites: SSPL Unit 1 and SSPL Unit 2. Please find attached a brief presentation...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
endo-9-Methyl-9-azabicyclo [3.3.1] nonan-3-amime
CAS Number : 76272-56-5
End Use API : Granisetron
About The Company : Ceyone Life Sciences specializes in providing research-oriented chemistry services and manufacturing niche chemicals, intermediates, and APIs. The company is fo...
1-Methylindazole-3-carboxylic acid
CAS Number : 50890-83-0
End Use API : Granisetron
About The Company : Ceyone Life Sciences specializes in providing research-oriented chemistry services and manufacturing niche chemicals, intermediates, and APIs. The company is fo...
Endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane
CAS Number : 76272-56-5
End Use API : Granisetron
About The Company : We specialize in the supply of API and API related intermediates and services. A significant part of our business comes from the process/production development ...
1-Methylindazole-3-carboxylic acid
CAS Number : 50890-83-0
End Use API : Granisetron
About The Company : We specialize in the supply of API and API related intermediates and services. A significant part of our business comes from the process/production development ...
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
53
PharmaCompass offers a list of Granisetron API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Granisetron manufacturer or Granisetron supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Granisetron manufacturer or Granisetron supplier.
PharmaCompass also assists you with knowing the Granisetron API Price utilized in the formulation of products. Granisetron API Price is not always fixed or binding as the Granisetron Price is obtained through a variety of data sources. The Granisetron Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A SUSTOL manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of SUSTOL, including repackagers and relabelers. The FDA regulates SUSTOL manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. SUSTOL API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of SUSTOL manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A SUSTOL supplier is an individual or a company that provides SUSTOL active pharmaceutical ingredient (API) or SUSTOL finished formulations upon request. The SUSTOL suppliers may include SUSTOL API manufacturers, exporters, distributors and traders.
click here to find a list of SUSTOL suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A SUSTOL DMF (Drug Master File) is a document detailing the whole manufacturing process of SUSTOL active pharmaceutical ingredient (API) in detail. Different forms of SUSTOL DMFs exist exist since differing nations have different regulations, such as SUSTOL USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A SUSTOL DMF submitted to regulatory agencies in the US is known as a USDMF. SUSTOL USDMF includes data on SUSTOL's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The SUSTOL USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of SUSTOL suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a SUSTOL Drug Master File in Korea (SUSTOL KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of SUSTOL. The MFDS reviews the SUSTOL KDMF as part of the drug registration process and uses the information provided in the SUSTOL KDMF to evaluate the safety and efficacy of the drug.
After submitting a SUSTOL KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their SUSTOL API can apply through the Korea Drug Master File (KDMF).
click here to find a list of SUSTOL suppliers with KDMF on PharmaCompass.
A SUSTOL written confirmation (SUSTOL WC) is an official document issued by a regulatory agency to a SUSTOL manufacturer, verifying that the manufacturing facility of a SUSTOL active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting SUSTOL APIs or SUSTOL finished pharmaceutical products to another nation, regulatory agencies frequently require a SUSTOL WC (written confirmation) as part of the regulatory process.
click here to find a list of SUSTOL suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing SUSTOL as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for SUSTOL API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture SUSTOL as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain SUSTOL and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a SUSTOL NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of SUSTOL suppliers with NDC on PharmaCompass.
SUSTOL Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of SUSTOL GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right SUSTOL GMP manufacturer or SUSTOL GMP API supplier for your needs.
A SUSTOL CoA (Certificate of Analysis) is a formal document that attests to SUSTOL's compliance with SUSTOL specifications and serves as a tool for batch-level quality control.
SUSTOL CoA mostly includes findings from lab analyses of a specific batch. For each SUSTOL CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
SUSTOL may be tested according to a variety of international standards, such as European Pharmacopoeia (SUSTOL EP), SUSTOL JP (Japanese Pharmacopeia) and the US Pharmacopoeia (SUSTOL USP).